In Candida albicans, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1

被引:20
作者
Odds, Frank C. [1 ]
机构
[1] Univ Aberdeen, Sch Med Sci, Aberdeen Fungal Grp, Aberdeen AB25 2ZD, Scotland
关键词
antifungal agent; Candida albicans; terbinafine; flucytosine; azole antifungal; caspofungin; MLST; VIRUS-INFECTED PATIENTS; AZOLE CROSS-RESISTANCE; IN-VITRO ACTIVITIES; ANTIFUNGAL RESISTANCE; MOLECULAR-MECHANISMS; FLUCONAZOLE; SUSCEPTIBILITY; VORICONAZOLE; YEASTS; CDR1;
D O I
10.1111/j.1567-1364.2009.00577.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A panel of 637 isolates of Candida albicans that had been typed by multilocus sequence typing (MLST) and tested for susceptibility to amphotericin B, caspofungin, fluconazole, flucytosine, itraconazole, ketoconazole, miconazole, terbinafine and voriconazole was the material for a statistical analysis of possible associations between antifungal susceptibility and other properties. For terbinafine and flucytosine, the greatest proportion of low-susceptibility isolates, judged by two resistance breakpoints, was found in MLST clade 1 and among isolates homozygous at the MAT locus, although only three isolates showed cross-resistance to the two agents. Most instances of low susceptibility to azoles, flucytosine and terbinafine were among oropharyngeal isolates from HIV-positive individuals. Statistically significant correlations were found between terbinafine and azole minimal inhibitory concentrations (MICs), while correlations between flucytosine MICs and azole MICs were less strong. It is concluded that a common regulatory mechanism may operate to generate resistance to the two classes of agent that inhibit ergosterol biosynthesis, terbinafine and the azoles, but that flucytosine resistance, although still commonly associated with MAT homozygosity, is differently regulated.
引用
收藏
页码:1091 / 1101
页数:11
相关论文
共 41 条
[1]  
[Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts
[2]  
Approved Standard, VThird
[3]   TERBINAFINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN SUPERFICIAL MYCOSES [J].
BALFOUR, JA ;
FAULDS, D .
DRUGS, 1992, 43 (02) :259-284
[4]   In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles [J].
Barchiesi, F ;
DiFrancesco, LF ;
Scalise, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1812-1814
[5]   Clade-related amphotericin B resistance among south African Candida albicans isolates [J].
Blignaut, E ;
Molepo, J ;
Pujol, C ;
Soll, DR ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (01) :29-31
[6]   Collaborative consensus for optimized multilocus sequence typing of Candida albicans [J].
Bougnoux, ME ;
Tavanti, A ;
Bouchier, C ;
Gow, NAR ;
Magnier, A ;
Davidson, AD ;
Maiden, MCJ ;
d'Enfert, C ;
Odds, FC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :5265-5266
[7]   Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods [J].
Cantón, E ;
Pemán, J ;
Gobernado, M ;
Viudes, A ;
Espinel-Ingroff, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1593-1596
[8]   Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis [J].
Cartledge, JD ;
Midgley, J ;
Gazzard, BG .
AIDS, 1997, 11 (15) :1839-1844
[9]  
Cernicka J, 2006, INT J ANTIMICROB AG, V27, P403, DOI 10.1016/j.ijantimicag.2005.12.005
[10]   A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans [J].
Coste, A ;
Turner, V ;
Ischer, F ;
Morschhäuser, J ;
Forche, A ;
Selmecki, A ;
Berman, J ;
Bille, J ;
Sanglard, D .
GENETICS, 2006, 172 (04) :2139-2156